


Claims

1. A compound of formula (I):



5 wherein

R^1 represents C_{1-3} alkyl or halogen;

R^2 represents C_{1-3} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, halogen, C_{1-3} alkoxy, amino, cyano or n hydroxy;

m represents an integer from 0 to 4;

10 n represents an integer from 0 to 2;

A-B represents $-NR^5-SO_2-$ or $-NR^5-CO-$;

R^5 represents hydrogen, C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, C_{3-10} cycloalkyl, $-C_{0-6}$ alkyl-aryl, $-C_{0-6}$ alkyl-heteroaryl, $-C_{0-6}$ alkyl-heterocyclyl, $-C_{3-10}$ cycloalkyl-aryl or $-C_{3-10}$ cycloalkyl-heteroaryl;

15 $-W-$ represents $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-C(H)=C(H)-$ or $-CH_2-C(H)=C(H)-$;

X-Y-Z represents $-C=CR^8-NR^9-$;

R^8 represents hydrogen, C_{1-6} alkyl or C_{3-10} cycloalkyl;

R^9 represents hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-10} cycloalkyl, $-C_{0-6}$ alkyl-aryl, $-C_{0-6}$ alkyl-heteroaryl, $-C_{0-6}$ alkyl-heterocyclyl, $-C_{3-10}$ cycloalkyl-aryl, $-C_{3-10}$ cycloalkyl-heteroaryl, $-COOR^{12a}$, $-OR^{12a}$, $-CONR^{12a}R^{13a}$, $-SO_2NR^{12a}R^{13a}$, $-COC_{1-6}$ alkyl, $-COC_{3-10}$ cycloalkyl, $-CO-$ aryl, $-CO-heteroaryl$, $-COC_{1-6}$ alkyl-aryl, $-COC_{1-6}$ alkyl-heteroaryl, $-COC_{3-10}$ cycloalkyl-aryl, $-COC_{3-10}$ cycloalkyl-heteroaryl, $-SO_2C_{1-6}$ alkyl, $-SO_2C_{3-10}$ cycloalkyl, $-SO_2$ aryl, $-SO_2$ heteroaryl, $-SO_2C_{1-6}$ alkyl-aryl, $-SO_2C_{1-6}$ alkyl-heteroaryl, $-SO_2C_{3-10}$ cycloalkyl-aryl or $-SO_2C_{3-10}$ cycloalkyl-heteroaryl (wherein R^{12a} and R^{13a} independently represent

25 hydrogen, C_{1-6} alkyl or C_{3-10} cycloalkyl);

R^3 represents C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $-C_{1-6}$ alkyl- C_{3-10} cycloalkyl, $-C_{0-6}$ alkyl-aryl, $-C_{0-6}$ alkyl-heteroaryl or $-C_{0-6}$ alkyl-heterocyclyl;

R^4 represents hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, C_{3-10} alkynyl, $-C_{3-10}$ cycloalkyl, $-C_{3-10}$ cycloalkenyl, $-C_{0-6}$ alkyl-aryl, $-C_{0-6}$ alkyl-heteroaryl, $-C_{0-6}$ alkyl-heterocyclyl, $-C_{1-6}$ alkyl- C_{3-10} cycloalkyl, $-C_{3-10}$ cycloalkyl-aryl, $-C_{3-10}$ cycloalkyl-heteroaryl, $-C_{3-10}$ cycloalkyl-heterocyclyl, $-C_{3-10}$ cycloalkyl- C_{1-6} alkyl-aryl, $-heterocyclyl-aryl$, $-C_{1-6}$ alkyl-aryl-heteroaryl, $-C(R^aR^b)-CONH-C_{1-6}$ alkyl, $-C(R^aR^b)-CONH-C_{3-10}$ cycloalkyl, $-C_{2-6}$ alkyl-S- C_{1-6} alkyl, $-C_{2-6}$ alkyl- NR^cR^d , $-C(R^aR^b)-C_{1-6}$ alkyl, $-C(R^aR^b)-C_{0-6}$ alkyl-aryl, $-C(R^aR^b)-C_{0-6}$ alkyl-heteroaryl, $-C(R^aR^b)-C_{0-6}$ alkyl-heterocyclyl, $-C_{2-6}$ alkyl-O- C_{0-6} alkyl-aryl, $-C_{2-6}$ alkyl-O- C_{0-6} alkyl-heteroaryl or $-C_{2-6}$ alkyl-O- C_{0-6} alkyl-heterocyclyl;

35

R^a and R^b independently represent hydrogen, C₁₋₆ alkyl or R^a and R^b together with the carbon atom to which they are attached may form a C₃₋₁₀ cycloalkyl or heterocyclyl group;

- 5 R^c and R^d independently represent hydrogen, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl or R^c and R^d together with the nitrogen atom to which they are attached may form a nitrogen containing heterocyclyl group;
- wherein said alkyl, alkenyl, alkynyl and cycloalkyl groups may be optionally substituted by one or more (e.g. 1 to 6) halogen, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, haloC₁₋₆ alkyl, C₁₋₆ alkoxy, haloC₁₋₆ alkoxy, amino, cyano, hydroxy, -COOR²², -S-C₁₋₆ alkyl or -C₁₋₆ alkyl-
- 10 NR⁶R⁷ (wherein R⁶ and R⁷ independently represent hydrogen, C₁₋₆ alkyl or C₃₋₁₀ cycloalkyl) groups; and
- wherein said aryl, heteroaryl or heterocyclyl groups may be optionally substituted by one or more (e.g. 1 to 6) C₁₋₆ alkyl, halogen, haloC₁₋₆ alkyl, haloC₁₋₆ alkoxy, oxo, hydroxy, C₁₋₆ alkoxy, C₂₋₆ alkynyl, C₂₋₆ alkenyl, amino, cyano, nitro, -COOR²², -NR²²COR²³, -
- 15 CONR²²R²³, -SO₂NR²²R²³, -NR²²R²³, -C₁₋₆ alkyl-NR²²R²³, -C₁₋₆ alkyl-O-C₁₋₆ alkyl or -C₁₋₆ alkanoyl groups (wherein R²² and R²³ independently represent hydrogen, C₁₋₆ alkyl or C₃₋₁₀ cycloalkyl);
- or a pharmaceutically acceptable salt or solvate thereof.

- 20 2. A compound according to claim 1 which is a compound of formula E1-E90 or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt or solvate thereof in admixture
- 25 with one or more pharmaceutically acceptable diluents or carriers.
4. A compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt or solvate thereof for use as a pharmaceutical.
- 30 5. Use of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt or solvate thereof in the treatment of diseases characterised by elevated β -amyloid levels or β -amyloid deposits.
6. Use of a compound of formula (I) as defined in claim 1 or claim 2 or a
- 35 pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of diseases characterised by elevated β -amyloid levels or β -amyloid deposits.
7. A method of treatment or prophylaxis of diseases characterised by elevated β -
- 40 amyloid levels or β -amyloid deposits which comprises administering to a patient an effective amount of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt or solvate thereof.

8. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of diseases characterised by elevated β -amyloid levels or β -amyloid deposits.
- 5